Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in Renal Cell Carcinoma) study underscore the critical role of tumor size reduction in improving survival outcomes for patients with advanced renal cell carcinoma (aRCC).
Leave A Comment